| Kelly Layton, RN | |
|
1088 Highway 34, Aberdeen, NJ 07747-1948 | |
| (732) 290-1700 | |
| (732) 290-0040 |
| Full Name | Kelly Layton |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Psychiatric/mental Health |
| Location | 1088 Highway 34, Aberdeen, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497372338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WP0808X | Registered Nurse - Psychiatric/mental Health | 26NR19000100 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Layton, RN 1088 Highway 34, Aberdeen, NJ 07747-1948 Ph: () - | Kelly Layton, RN 1088 Highway 34, Aberdeen, NJ 07747-1948 Ph: (732) 290-1700 |
News Archive
Buprenorphine (BUP) is approved for the treatment of opioid addiction. The current dosing regimen of BUP in pregnant women is based on recommendations designed for non-pregnant adults, but physiological changes during pregnancy may alter BUP exposure and efficacy.
An international study, involving scientists at the University of Southampton, has used an analysis of epigenetic marks on DNA to measure how much a baby's development in the womb is determined by the genes inherited from the parents, as compared with the mother's nutrition, mental health and lifestyle.
Periodontitis is a risk factor for heart disease. Now a team of researchers has shown that a periodontal pathogen causes changes in gene expression that boost inflammation and atherosclerosis in aortic smooth muscle cells. The research is published ahead of print in Infection and Immunity, a journal of the American Society for Microbiology.
The Canadian Centre on Substance Abuse (CCSA) today announced that it will open Issues of Substance (IOS) 2009, Canada's biennial conference on substance abuse, with a focus on the role of treatment systems. More than 13 sessions will examine the role of treatment from a variety of perspectives, including the Models of Care project in the UK, the National Treatment Strategy in Canada (NTS) and case study and research presentations reviewing the effectiveness of a variety of integrated programs in Canada.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
› Verified 3 days ago
Sandra H Pollonais, R,N Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 33 Aberdeen Road Apt 347b, Aberdeen, NJ 07747 Phone: 917-365-4441 | |
Marie M. Marcelin, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1088 Highway 34, Aberdeen, NJ 07747 Phone: 732-290-1700 | |
Mary Dulsky, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1088 Highway 34, Aberdeen, NJ 07747 Phone: 732-290-1700 Fax: 732-290-0040 | |
Danielle Lazaro, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1088 Highway 34, Aberdeen, NJ 07747 Phone: 732-290-1700 Fax: 732-696-9998 | |
Lisa Corrado, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1088 Highway 34, Aberdeen, NJ 07747 Phone: 732-290-1700 Fax: 732-290-0040 | |
Joanne C Quinn, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1088 Highway 34, Aberdeen, NJ 07747 Phone: 732-790-1700 Fax: 732-290-0040 |